Arkema SA (OTCMKTS:ARKAY - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the eight brokerages that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company.
ARKAY has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded Arkema from a "hold" rating to a "buy" rating in a research report on Tuesday, February 10th. Kepler Capital Markets cut Arkema from a "strong-buy" rating to a "hold" rating in a report on Friday, February 27th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Arkema in a research note on Thursday. Finally, Zacks Research cut Arkema from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 6th.
Get Our Latest Report on ARKAY
Arkema Stock Down 2.5%
Shares of ARKAY stock opened at $70.66 on Tuesday. The stock has a market cap of $5.37 billion, a P/E ratio of 81.22 and a beta of 0.84. Arkema has a 52 week low of $56.28 and a 52 week high of $79.36. The company has a quick ratio of 1.63, a current ratio of 2.13 and a debt-to-equity ratio of 0.54. The company's fifty day simple moving average is $67.81 and its two-hundred day simple moving average is $62.98.
About Arkema
(
Get Free Report)
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total's chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema's operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arkema, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arkema wasn't on the list.
While Arkema currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.